Concern about use of anthrax as a bioweapon prompted development of novel anthrax antitoxins for treatment. Clinical guidelines for the treatment of anthrax recommend antitoxin therapy in combination with intravenous antimicrobials; however, a large-scale or mass anthrax incident may exceed antitoxin availability and create a need for judicious antitoxin use. We conducted a systematic review of antitoxin treatment of inhalation anthrax in humans and experimental animals to inform antitoxin recommendations during a large-scale or mass anthrax incident. A comprehensive search of 11 databases and the FDA website was conducted to identify relevant animal studies and human reports: 28 animal studies and 3 human cases were identified. Antitoxin monotherapy at or shortly after symptom onset demonstrates increased survival compared to no treatment in animals. With early treatment, survival did not differ between antimicrobial monotherapy and antimicrobial-antitoxin therapy in nonhuman primates and rabbits. With delayed treatment, antitoxin-antimicrobial treatment increased rabbit survival. Among human cases, addition of antitoxin to combination antimicrobial treatment was associated with survival in 2 of the 3 cases treated. Despite the paucity of human data, limited animal data suggest that adjunctive antitoxin therapy may improve survival. Delayed treatment studies suggest improved survival with combined antitoxin-antimicrobial therapy, although a survival difference compared with antimicrobial therapy alone was not demonstrated statistically. In a mass anthrax incident with limited antitoxin supplies, antitoxin treatment of individuals who have not demonstrated a clinical benefit from antimicrobials, or those who present with more severe illness, may be warranted. Additional pathophysiology studies are needed, and a point-of-care assay correlating toxin levels with clinical status may provide important information to guide antitoxin use during a large-scale anthrax incident.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710135 | PMC |
| http://dx.doi.org/10.1089/hs.2015.0032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Toxin and capsule production by Bacillus cereus biovar anthracis influence pathogenicity in macrophages and animal models.
PLoS Negl Trop Dis
December 2024
Emerging Pathogens Institute, University of Florida, Gainesville, Florida, United States of America.
Bacillus cereus biovar anthracis (Bcbva) causes anthrax-like disease in animals, particularly in the non-human primates and great apes of West and Central Africa. Genomic analyses revealed Bcbva as a member of the B. cereus species that carries two plasmids, pBCXO1 and pBCXO2, which have high sequence homology to the B.
View Article and Find Full Text PDFRoles of host and environment in shift of primary anthrax host species in Kruger National Park.
PLoS One
December 2024
Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa.
Environmental and climatic factors, as well as host demographics and behaviour, significantly influence the exposure of herbivorous mammalian hosts to pathogens such as Bacillus anthracis, the causative agent of anthrax. Until the early 1990s in Kruger National Park (KNP), kudu (Tragelaphus strepsiceros) was the host species most affected by anthrax, with outbreaks occurring predominantly in the dry season, particularly during drought cycles. However, the most affected host species has shifted to impala (Aepyceros melampus), with more frequent anthrax outbreaks during the wet season.
View Article and Find Full Text PDFInvestigating suspected gastrointestinal anthrax: a case-control study in Cayapa village, Abra province, Philippines, March 2017.
Western Pac Surveill Response J
December 2024
Department of Health, Manila, Philippines.
Article Synopsis
- * A case-control study identified 29 cases of illness linked to symptoms like abdominal pain, fever, and diarrhoea, with a significant risk factor being the consumption of butchered meat from a dead carabao.
- * The findings suggest that the outbreak was caused by eating the dead carabao, highlighting the need for better education on zoonotic disease prevention in farming communities.
Are we ready for the next anthrax outbreak? Lessons from a simulation exercise in a rural-based district in Uganda.
Epidemiol Infect
December 2024
Department of Wildlife, Animal Resources Management, College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere University, Kampala, Uganda.
Anthrax is a bacterial zoonotic disease caused by We qualitatively examined facilitators and barriers to responding to a potential anthrax outbreak using the capability, opportunity, motivation behaviour model (COM-B model) in the high-risk rural district of Namisindwa, in Eastern Uganda. We chose the COM-B model because it provides a systematic approach for selecting evidence-based techniques and approaches for promoting the behavioural prompt response to anthrax outbreaks. Unpacking these facilitators and barriers enables the leaders and community members to understand existing resources and gaps so that they can leverage them for future anthrax outbreaks.
View Article and Find Full Text PDFAnthrax meningoencephalitis: A case report.
Exp Ther Med
January 2025
Department of Neurosurgery, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China.
The present study describes the case of a patient with anthrax meningoencephalitis with the aim of providing a scientific basis for the control of this disease. The cerebrospinal fluid and blood of the patient were tested for genes and was detected. The patient's meningitis was cured following treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!